Kyle Bergacker joins Sam Vadas to discuss Novo Nordisk (NVO) earnings. Shares of the biotech pharmaceutical company are down following its 2Q report. Kyle discusses the lowered sales growth in its guidance as well as combatting "copy cat" medications from telehealth companies. He adds commentary on the company's GLP-1 weight loss drugs and what it means in regards to the long-term outlook for Novo Nordisk.